drugset

drugset / Trial / NCT00626327

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327 ↗

Phase 3 Completed 1630 enrolled Novartis Vaccines

RandomizedSingle-groupOpen-labelPrevention

Summary

Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers

Timeline

Start: 2008-02
Primary completion: 2010-07
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	MMRV	Vaccine	—	—
Subject	Menveo	Vaccine	—	—

Indications